Cargando…

Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer

Most patients with advanced non-small cell lung cancer (NSCLC) do not achieve a durable remission after treatment with immune checkpoint inhibitors. Here we report the clinical history of an exceptional responder to radiation and anti-program death-ligand 1 (PD-L1) monoclonal antibody, atezolizumab,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coffey, David G., Xu, Yuexin, Towlerton, Andrea M. H., Kowanetz, Marcin, Hegde, Priti, Darwish, Martine, Yadav, Mahesh, Blanchette, Craig, Ruppert, Shannon M., Bertino, Sarah, Xu, Qikai, Ferretti, Andrew, Weinheimer, Adam, Hellmann, Matthew, Qin, Angel, Thomas, Dafydd, Warren, Edus H., Ramnath, Nithya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500393/ https://www.ncbi.nlm.nih.gov/pubmed/36159875 http://dx.doi.org/10.3389/fimmu.2022.961105

Ejemplares similares

Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer
por: Qin, Angel, et al.
Publicado: (2016)

Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
por: Fehlings, Michael, et al.
Publicado: (2019)

Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma
por: Xu, Yuexin, et al.
Publicado: (2019)

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
por: Patil, Namrata S., et al.
Publicado: (2021)

Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2019)

Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes
por: Xu, Yuexin, et al.
Publicado: (2022)

Serial Analysis of the T-Cell Receptor β-Chain Repertoire in People Living With HIV Reveals Incomplete Recovery After Long-Term Antiretroviral Therapy
por: Towlerton, Andrea M. H., et al.
Publicado: (2022)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
por: Powles, Thomas, et al.
Publicado: (2015)

Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
por: Xu, Yuexin, et al.
Publicado: (2021)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
por: Kowanetz, Marcin, et al.
Publicado: (2018)

Immune escape from NY-ESO-1-specific T cell therapy via loss of heterozygosity in the MHC
por: Klippel, Zandra K., et al.
Publicado: (2014)

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
por: Molinero, Luciana, et al.
Publicado: (2019)

Building capacity in the conservation of exceptional plant species
por: Philpott, Megan, et al.
Publicado: (2022)

A CD4/Foxp3/OX40 triple immunofluorescence assay determines association between T cell immune subsets and outcome in colorectal cancer
por: Ziai, James, et al.
Publicado: (2014)

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
por: Wallin, Jeffrey J., et al.
Publicado: (2016)

Single cell atlas of kidney cancer endothelial cells reveals distinct expression profiles and phenotypes
por: Xu, Yuexin, et al.
Publicado: (2023)

Comparative molecular characterization of typical and exceptional responders in glioblastoma
por: Wipfler, Kristin, et al.
Publicado: (2018)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Phenotypic and Transcriptional Fidelity of Patient-Derived Colon Cancer Xenografts in Immune-Deficient Mice
por: Chou, Jeffrey, et al.
Publicado: (2013)

Two Cases of Atezolizumab-Induced Hypophysitis
por: Kanie, Keitaro, et al.
Publicado: (2017)

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
por: Lambert, Nicolas, et al.
Publicado: (2022)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

An exceptional vaccination policy in exceptional circumstances
por: The Lancet Infectious Diseases
Publicado: (2021)

Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions
por: Zhang, Zhuo, et al.
Publicado: (2015)

Reactive Oxygen Species in the Tumor Microenvironment: An Overview
por: Weinberg, Frank, et al.
Publicado: (2019)

Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches
por: Sankar, Kamya, et al.
Publicado: (2021)

Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B
por: Potts, Malia B., et al.
Publicado: (2015)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
por: Hellmann, Matthew D., et al.
Publicado: (2020)

Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system
por: Miller, Chris P., et al.
Publicado: (2023)

Exceptional music pedagogy for children with exceptionalities : international perspectives
Publicado: (2016)

CMS : An exceptional load for an exceptional work site
Publicado: (2001)

Exceptional Values of Meromorphic Function on Annulus
por: Xu, Hong-Yan
Publicado: (2013)

Collagenous colitis and atezolizumab therapy: an atypical case
por: Gallo, Antonella, et al.
Publicado: (2020)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM
por: Ma, Jennifer, et al.
Publicado: (2016)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Exceptional Responder to Immunotherapy: A Rare Case of Post-HSCT DLBCL Relapse Responding to Nivolumab
por: Madabhavi, Irappa, et al.
Publicado: (2019)

Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
por: Zhang, Fei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k28pftrrst7uhgtsj9cf1gkfl1